

Additrace®

| | |
|--------------------------------------|--|
| Form | <p>10mL vial: Each vial contains Iron, Zinc, Manganese, Copper, Chromium, Selenium, Molybdenum, Fluoride and Iodide in trace amounts.</p> <p>Each vial contains less than 1mmol of both potassium and sodium.</p> |
| Reconstitution | <p>Already in solution</p> <p>Dilute further before administration</p> |
| Compatibility & Stability | <p>Glucose 5%</p> <p>Sodium Chloride 0.9%</p> |
| Administration | <p>Do not use if solution is cloudy or has sediments.</p> <p>IV infusion</p> <p>Add 10mL of Additrace® to 100mL of compatible infusion fluid and administer over 2 - 3 hours.</p> <p>Preferably administer via a central venous access device to avoid potential venous irritation. If given peripherally, choose a large vein and monitor the injection site closely.</p> |
| Extravasation | <p>Extravasation is likely to cause tissue damage due to low pH.</p> |
| Additional Information | <ul style="list-style-type: none"> • Additrace® is normally administered in conjunction with Parenteral Nutrition. • For patients prescribed Additrace®, Solivito N®, and Vitlipid N Adult®, or a combination of these, they can be infused together in 100mL glucose 5% or sodium chloride 0.9% over 2 - 3 hours. • Additrace® should be used with caution in patients with impaired biliary and/or impaired renal function in whom excretion of trace elements may be significantly decreased. • Use with caution in patients with biochemical or clinical evidence of liver dysfunction (especially cholestasis). • If treatment is to continue for more than 4 weeks, check manganese levels. |

Information provided relates to Additrace® manufactured by Fresenius Kabi.